TScan Gets FDA Clearance of Investigational New Drug Application for Cancer Treatment
Provided by
Dow Jones
By Chris Wack
TScan Therapeutics said Tuesday that the U.S. Food and Drug Administration has cleared its investigational new drug application for TSC-203-A0201, a TCR-T targeting preferentially expressed antigen in melanoma.
The clinical-stage biopharmaceutical company said TSC-203-A0201 is the fourth TCR-T cleared for clinical development in the company's solid tumor program.
TScan said it is on-track to treat the first patient with a TScan TCR-T and report preliminary data by the end of 2023.
TScan shares were up 8% to $2.37 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 29, 2023 07:47 ET (11:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
United States